Citations

Clear

334 citation(s) found for "Jacobs, C".

Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium.
Dahiya, Saurabh , Hill, Brian T. , Lekakis, Lazaros J. , Neelapu, Sattva S. , Wang, Michael , Jain, Preetesh , Wang, Yucai , Locke, Frederick L. , Muñoz, Javier , Beitinjaneh, Amer , Frank, Matthew J. , Jacobs, Miriam T. , Miklos, David B. , Ghobadi, Armin , Lin, Yi , Jain, Michael D. , Maurer, Matthew J.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e19583-e19583

10.1200/jco.2022.40.16_suppl.e19583 Get It

e19583 Background: Brexucabtagene autoleucel (BA) is an FDA approved therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL), based on results from ZUMA-2 study. We report the safety and efficacy of BA in standard of care practice among centers in the US Lymphoma CAR-T Consortium. Methods: 16 centers participated in this retrospective study. Patients (pts) who underwent leukapheresis by 12/31/2021 with an intent to manufacture BA were included. Baseline clinical characteristics, bridging therapy, adverse events after BA infusion, and post-infusion outcome data were collected. Eligibility for ZUMA-2 was retrospectively determined. Survival outcomes were analyzed using the Kaplan-Meier method. Results: At the data cut-off date, 189 pts underwent leukapheresis, among whom 167 (88%) completed BA infusion, 22 (12%) did not receive infusion. The median age was 67 years. 16% had high risk simplified MIPI, 57% had Ki-67≥50%, 41% had aggressive histology, 49% had TP53 alteration, 51% with POD24 and 10% had CNS involvement. The median number of prior lines of therapy was 3 (range 1-10). 86% had prior BTKi treatment (89% refractory). 130 (78%) pts would not have met ZUMA-2 eligibility criteria. 113 (68%) pts received bridging therapy, which included BTKi, venetoclax, chemotherapy. Median time from leukapheresis to lymphodepletion chemotherapy: 28 days (range 17-140). Cytokine release syndrome (CRS) rate was 90% (8% grade ≥3; 1 grade 5), and immune effector cell-associated neurotoxicity syndrome (ICANS) rate was 61% (32% grade ≥3). Grade 5 ICANS (n = 0). Medications used to manage CRS and ICANS were 125 (76%) for tocilizumab, 112 (68%) for corticosteroid, and 27 (16%) for anakinra. 32 (20%) pts required ICU admission, 18 pts required vasopressors, and 5 pts required mechanical ventilation. Day 30 response was evaluable in 155 pts (89% ORR, 70% CR). The best ORR was 89%, with 80% CR, 9% PR. The ORR/CR rates were 88%/79% for aggressive histology, 89%/77% for high Ki-67% (> 50%), 90%/72% for TP53 altered, 81%/75% for CNS involved, 89%/79% for BTKi-exposed, 91%/83% for BTKi-naïve, and 89%/78% for those not meeting ZUMA-2 eligibility criteria. The median duration of response was not reached and at 6-month was 67% (95% CI 57-75). With a median follow-up of 5.6 months (range 0.2-15.3), median PFS was not reached, the 6-month PFS rate was 63% (95% CI 54-71), and median OS was 15.3 months and the 6-month OS rate was 85% (95% CI 77-90). Conclusions: This multicenter retrospective study demonstrated encouraging safety and efficacy data of BA in R/R MCL in the real-world practice. Despite 78% of the pts being ineligible for ZUMA-2, the responses, CRS, ICANS and outcomes were comparable to ZUMA-2 data. Long term safety and efficacy will be reported.
Supporting patients with metastatic breast cancer during therapy with cyclin-dependent kinase 4/6 (CDK) inhibitors: A needs assessment.
O’Sullivan, Ciara C. , Jacobs, Ginny, Perez, Domingo Gregorio, Jackson, Katrina, Schowengerdt, Bethany , McFadden, Pam, Jacobs, Ginny , Jackson, Katrina, Lazure, Patrice

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e13054-e13054

10.1200/jco.2022.40.16_suppl.e13054 Get It

e13054 Background: Combination therapy with cyclin dependent kinase 4 and 6 inhibitors (CDK4/6i: palbociclib, ribociclib and abemaciclib) and endocrine therapy (ET) has markedly improved treatment of hormone receptor positive (HR+), HER2-negative (-) advanced or metastatic breast cancer (MBC) worldwide.However, data is limited on why patients may discontinue CDK4/6i based therapy and how healthcare providers (HCPs) see their role in educating patients (Px) about side effects and supporting compliance. Objective: This study identifies reasons for suboptimal compliance and early discontinuation of CDK4/6i in US HR+ HER2- MBC Px, with a focus on HCPs and Px educational needs related to on-treatment monitoring, side effects and symptom management. Methods: A sequential mixed-methods design was used; 45-minute phone interviews (n=25) informed the development of an online survey (n=193). Both phases included HCPs comprising medical oncologists (ONCs), oncology registered nurses (RNs), nurse practitioners, and physician assistants (NPs/PAs) in community-based settings. Results: Identified areas of improvement for HCPs included: suboptimal competencies were identified: educating Px adequately regarding potential side effects and engaging them to monitor, report, and address them. Among HCPs surveyed, 26%-48% reported suboptimal knowledge of side effects of specific CDK4/6i [Table]. Interviewees noted that educating Px and setting expectations on potential side effects was critical, but 52% of ONCs reported suboptimal skill doing so. A majority of HCPs (68%-91%) expect Px to be able to report all side effects, with half of ONCs considering compliance with medication entirely Pxs’ responsibility, compared with NPs/PAs and RNs at 16-17%. Conclusions: This study identified areas where HCPs can improve their ability to counsel Px and address concerns that may influence a Px’s decision to prematurely discontinue therapy and should be used to inform future professional development initiatives. [Table: see text]
SARS-CoV-2 Viremia Is Associated with Lower Respiratory Tract Viral Load and Plasma Markers of Epithelial Injury and Thrombin Generation in Critically Ill Patients
Bittner, M.J., Jacobs, Jordan, Naqvi, Asma , Meyer, Michael, Methé, Barbara A. , Neal, M. , Lee, J., Morris, Alison , McVerry, Bryan J , Shah, Faraaz A , Mellors, John W , Seheult, Jansen N. , Kitsios, Georgios D , Bain, William G

Mayo Clinic

B57. CUTTING EDGE COVID RESEARCH | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A3144-A3144

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a3144 Get It

Airway Mucus Plugs on CT Scan Are Associated with Worse Patient Reported Outcomes in Smokers with and Without COPD and No History of Exacerbations: A Cross Sectional Analysis of the COPDGene Study
Kim, V., Orejas, J. , Yen, A., Kligerman, S.J., Manapragada, Padma P. , Jacobs, K., Abozeed, Mostafa , Zahid, Mohd , Sonavane, S., Terry, Nina , Nath, H.P., Investigators, COPDGene, Kim, V., Dolliver, Wojciech Remington , Grumley, Scott , Yen, A.A., Kligerman, Seth , Aziz, M.A., Ahmed, Ali , Estépar, Raúl San Jośe , Díaz, Alejandro A.

Mayo Clinic

A22. IMAGING AND MOLECULAR BIOMARKERS IN COPD | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A1076-A1076

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a1076 Get It

119 Current Practices in High and Low Volume Centers Regarding Corporotomy Localization During Penoscrotal Inflatable Penile Implant Surgery
Barnard, J, Renterghem, K. Van, Jacobs, B, Yafi, FA, Barnard, J, Barnard, J, Osmonov, Daniar , Ralph, David , Ziegelmann, Matthew , Wang, R, Kannady, Chris, Lentz, A, García, E. Lutz, Adrianne, R, Bettochi, Carlo, Hatzichristodoulou, G, Gross, Madeleine, Faix, A. , Otero, JR, Barnard, John Taylor , Barnard, J, Barnard, J, Barnard, J, Venturino, Luca , WANG, RY, Lentz, A, Adrianne, R., Hatzichristodoulou, Georgios , Martínez‐Salamanca, Juan Ignacio

Mayo Clinic

The Journal of Sexual Medicine | April 26, 2022 | Volume: 19 | Issue: Supplement_1 | Pages: S60-S62

10.1016/j.jsxm.2022.01.383 Get It

ABSTRACT Introduction Literature concerning corporotomy location in multi-component inflatable penile prosthetic surgery via a penoscrotal approach is scarce if not non-existent. However, corporotomy location represents an important issue that may influence immediate and long-term outcomes regarding patient and partner satisfaction as well as device durability. Objective To report practices in low- and high-volume penile implant centers regarding corporotomy location. Methods Data from 18 (13 European and 5 American) implant centers were collected retrospectively between September 1st, 2018 and August 31st, 2019. Variables included: intraoperative proximal and distal corpus cavernosum length measurement, total corporal length measurement, total penile implant cylinder length, and length of rear tip extenders. Additionally, patient characteristics, indication for penile implant, operative time, type of implant utilized, reservoir characteristics and short term complications were reported. Results 809 virgin penile implant cases were included in the analysis. Mean age of participants was 61.5 +/- 9.6 years old. In total, 299 AMS 700TM (Boston Scientific) and 510 Coloplast Titan® devices were implanted. The mean proximal/distal corporal measurement ratio during corporotomy was 0.93 +/- 0.29. A statistically significant correlation between lower proximal /distal measurement ratio and higher age (p=0.0013), lower BMI (p<0.0001), use of rear tip extenders (RTE) (p=0.04), lower RTE length (p<0.0001) and absence of diabetes (p=0.0004) was reported. In a 3-month follow up period 49 complications and 37 revision procedures were reported. Conclusions This is the first study reporting and evaluating the current practices regarding corporotomy location during IPP placement in a multicenter cohort, particularly when including such a high number of patients. Nevertheless, the retrospective design limits the study outcomes. Even in experienced hands proximal length measurement in relation to distal length measurement in penoscrotal IPP surgery is in many cases sub-optimal, particularly when the tubing-cylinder connection of each device is taken into account. Disclosure No
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants
Lowry, Kathryn P. , Geuzinge, H. Amarens , Stout, Natasha K. , Alagöz, Oğuzhan , Hampton, John M. , Koning, Harry J. de , Miglioretti, Diana L. , Ravesteyn, Nicolien T. van , Sprague, Brian L. , Tosteson, Anna N.A. , Weaver, Donald L. , Yaffe, Martin J. , Mandelblatt, Jeanne S. , Kurian, Allison W. , Auer, Paul L. , Berstein, Leslie, Carter, Brian D., Gaudet, Mia M. , Haiman, Christopher, Jacobs, Eric J. , John, Esther M. , Lindström, Sara , Martínez, Elena, Patel, Alpa V. , Reid, Sonya , Taylor, Jack A. , Teras, Lauren R., Vachon, Celine M. , Yao, Song, Ziogas, Argyrios, Goldgar, David E. , Chen, Chen , Chen, C , Miglioretti, Diana L , John, Esther M , Taylor, Jack A , de Koning, Harry J , Kurian, Allison W , Kerlikowske, Karla , Schechter, Clyde B. , Trentham‐Dietz, Amy , Yeh, Jennifer M. , Couch, Fergus J. , Hu, Chunling , Kraft, Peter , Polley, Eric C. , Robson, Mark E. , Hart, Steven N. , Nathanson, Katherine L. , Domchek, Susan M. , Ambrosone, Christine B. , Anton‐Culver, Hoda , Bandera, Elisa V. , Bertrand, Kimberly A. , Burnside, Elizabeth S. , Eliassen, A. Heather , Hodge, James M. , Hunter, David J. , Kooperberg, Charles , Lacey, James V. , Marchand, Loı̈c Le , Ma, Huiyan , Neuhausen, Susan L. , Newcomb, Polly A. , O’Brien, Katie M. , Olson, Janet E. , Ong, Irene M. , Pal, Tuya , Palmer, Julie R. , Rosenberg, Lynn A. , Sandler, Dale P. , Tamimi, Rulla M. , Teras, Lauren R. , Vachon, Celine M. , Weinberg, Clarice R. , Yadav, Siddhartha , Yao, Song , Weitzel, Jeffrey N.

Mayo Clinic

JAMA Oncology | February 17, 2022 | Volume: 8 | Issue: 4 | Pages: 587

10.1001/jamaoncol.2021.6204 | PMID 35175286 Get It

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Tri
Castro, Januario E. , Lengerke-Diaz, Paula A. , Luján, Juliana Vélez, Choi, Michael Y. , Moreno-Cortes, Eider , Forero-Forero, José Vicente , García-Robledo, Juan Esteban , Jacobs, C , McCarthy, Colin, Heinen, Alaina, Amaya-Chanaga, Carlos I., Moreno-Cortes, Eider F , Forero, Jose V , Jacobs, Chaja , Kipps, Thomas J , Castro, Januario E , Garcia-Robledo, Juan Esteban , Diaz, Paula A Lengerke , Kipps, Thomas J.

Mayo Clinic

Advances in Hematology | January 22, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-8

10.1155/2022/4450824 | PMID 35103064 Get It

Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation. We enrolled 32 therapy-naïve CLL patients to receive ibrutinib plus obinutuzumab, followed by single-agent ibrutinib. Patients could discontinue ibrutinib after 36 months with sustained complete response (CR). We evaluated treatment safety, efficacy, and outcomes after ibrutinib discontinuation. The overall response rate was 100%, 28% achieved a CR, and 12.5% achieved bone marrow undetectable minimal residual disease. At a three-year median follow-up, 91% remain in remission with 100% overall survival. Five patients in sustained CR stopped ibrutinib and have not progressed. Eight non-CR patients discontinued for other reasons, with only two progressing. The treatment was safe, with a lower IRR rate. All patients responded to treatment with longer time-to-progression after discontinuation of ibrutinib. Our data support the evaluation of ibrutinib discontinuation strategies in more extensive clinical trials (https://Clinicaltrials.gov Identifier https://clinicaltrials.gov/ct2/show/NCT02315768).
The Importance of Accurately Defining Gender and Sex in Pathology
Jacobs, Jeremy W. , Lever, J.E. Peabody , Lee, Yeonsoo Sara , Bryan, Katherine M. , Booth, Garrett S. , Njoku, Ihuoma , Araj, Ellen, Lee, Yeonsoo S, Park, Jason Y , Sara Lee, Yeonsoo , Jacobs, Jeremy W , Booth, Garrett , Arvisais‐Anhalt, Simone , Park, Jason Y.

Mayo Clinic

American Journal of Clinical Pathology | January 7, 2022 | Volume: 158 | Issue: 1 | Pages: 153-153

10.1093/ajcp/aqac008 | PMID 35150126 Get It

1063. ARGONAUT-V: Susceptibility of Multidrug-Resistant (MDR) Pseudomonas aeruginosa to Cefepime-Taniborbactam
Bethel, Christopher R. , Marshall, Steven H. , Fowler, Vance G. , Papp‐Wallace, Krisztina M. , Mack, Andrew R , Patel, Robin , van Duin, David , Fowler, Vance G. , Rhoads, Daniel D. , Jacobs, Michael R. , Akker, Focco van den , Six, David A. , Moeck, Greg , Bonomo, Robert A.

Mayo Clinic

Open Forum Infectious Diseases | December 5, 2021 | Volume: 8 | Issue: Supplement_1 | Pages: S623-S624

10.1093/ofid/ofab466.1257 Get It

Abstract Background P. aeruginosa is a Gram-negative pathogen responsible for many serious infections. MDR, both intrinsic and acquired, presents major clinical challenges. Taniborbactam (formerly VNRX-5133; Fig 1) is a β-lactamase inhibitor (BLI) characterized as a bicyclic boronate, uniquely possessing activity toward all four Ambler classes of β-lactamases, both serine and metallo, with the exception of class B IMP β-lactamases. The β-lactam-BLI (BL-BLI) combination cefepime-taniborbactam (FTB; Fig 1) is currently in phase 3 clinical trials. Structures of taniborbactam and cefepime. The β-lactamase inhibitor is in red and the β-lactam antibiotic is in black. Methods The activity of FTB was tested against 197 well-characterized clinical P. aeruginosa isolates that were part of PRIMERS (Platforms for Rapid Identification of MDR-Gram-negative bacteria and Evaluation of Resistance Studies). Nearly 58% of these strains were reported as carbapenem-non-susceptible. Porin changes, efflux pumps, and/or the presence of acquired class A or class B carbapenemases were previously reported. Broth microdilution minimum inhibitory concentrations (MICs) were determined by CLSI M07 Ed. 11 methods with custom Sensititre frozen panels and interpreted using CLSI M100 Ed. 30 breakpoints. American Type Culture Collection strains were used for quality control. FEP breakpoints were provisionally used for FTB, where taniborbactam was fixed at 4 µg/mL. Results Percent susceptibility to BL agents alone was 45.2% for imipenem (IPM), 55.8% for meropenem (MEM), 60.9% for ceftazidime (CAZ), and 67.0% for FEP. The addition of BLI to BL increased % susceptibility for MEM-vaborbactam (MVB), 56.9%; ceftolozane-tazobactam (C/T), 77.7%, CAZ-avibactam (CZA), 79.7%, and FTB, 82.7%. MIC50s were in the susceptible range for all drugs except IPM, which was intermediate, and all MIC90s were in the resistant range (Table 1). Taniborbactam reduced FEP MIC by 2-fold in 32% of isolates and ≥ 4-fold in 13% of isolates. Against carbapenem-non-susceptible strains, % susceptibilities were: FTB, 68.5%, CZA, 63.0%, C/T, 59.3%; and MVB, 21.3% (Table 2). MIC50 and MIC90 values (µg/mL) and percent susceptibility (%S) for all P. aeruginosa strains (n=197). AMK, amikacin; ATM, aztreonam; C/T, ceftolozane-tazobactam; CAZ, ceftazidime; CZA, ceftazidime-avibactam; FEP, cefepime; FTB, cefepime-taniborbactam; IPM, imipenem; MEM, meropenem; MVB, meropenem-vaborbactam; TZP, piperacillin-tazobactam; TOB, tobramycin. *The breakpoints for FEP and MEM alone were provisionally applied to FTB and MVB, respectively. Tazobactam, avibactam, and taniborbactam were fixed at 4 µg/mL, while vaborbactam was fixed at 8 µg/mL. Breakpoints from CLSI M100, 31st ed, 2021. MIC50 and MIC90 values (µg/mL) and percent susceptibility (%S) for the subset of carbapenem-non-susceptible P. aeruginosa strains (n=108). AMK, amikacin; ATM, aztreonam; C/T, ceftolozane-tazobactam; CAZ, ceftazidime; CZA, ceftazidime-avibactam; FEP, cefepime; FTB, cefepime-taniborbactam; IPM, imipenem; MEM, meropenem; MVB, meropenem-vaborbactam; TZP, piperacillin-tazobactam; TOB, tobramycin. *The breakpoints for FEP and MEM alone were provisionally applied to FTB and MVB, respectively. Tazobactam, avibactam, and taniborbactam were fixed at 4 µg/mL, while vaborbactam was fixed at 8 µg/mL. Breakpoints from CLSI M100, 31st ed, 2021. Conclusion Compared to MVB, CZA, and C/T, FTB demonstrated the greatest activity against the 197 P. aeruginosa strains tested, including many carbapenem-non-susceptible strains. Pending completion of clinical development, FTB may be a promising therapeutic option for MDR P. aeruginosa infections. Disclosures Robin Patel, MD, 1928 Diagnostics (Consultant)BioFire Diagnostics (Grant/Research Support)ContraFect Corporation (Grant/Research Support)Curetis (Consultant)Hylomorph AG (Grant/Research Support)IDSA (Other Financial or Material Support, Editor’s Stipend)Infectious Diseases Board Review Course (Other Financial or Material Support, Honoraria)Mammoth Biosciences (Consultant)NBME (Other Financial or Material Support, Honoraria)Netflix (Consultant)Next Gen Diagnostics (Consultant)PathoQuest (Consultant)PhAST (Consultant)Qvella (Consultant)Samsung (Other Financial or Material Support, Patent Royalties)Selux Diagnostics (Consultant)Shionogi & Co., Ltd. (Grant/Research Support)Specific Technologies (Consultant)TenNor Therapeutics Limited (Grant/Research Support)Torus Biosystems (Consultant)Up-to-Date (Other Financial or Material Support, Honoraria) Robin Patel, MD, BioFire (Individual(s) Involved: Self): Grant/Research Support; Contrafect (Individual(s) Involved: Self): Grant/Research Support; IDSA (Individual(s) Involved: Self): Editor’s stipend; NBME, Up-to-Date and the Infectious Diseases Board Review Course (Individual(s) Involved: Self): Honoraria; Netflix (Individual(s) Involved: Self): Consultant; TenNor Therapeutics Limited (Individual(s) Involved: Self): Grant/Research Support; to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Mammoth Biosciences and Qvella (Individual(s) Involved: Self): Consultant David van Duin, MD, PhD, Entasis (Advisor or Review Panel member)genentech (Advisor or Review Panel member)Karius (Advisor or Review Panel member)Merck (Grant/Research Support, Advisor or Review Panel member)Pfizer (Consultant, Advisor or Review Panel member)Qpex (Advisor or Review Panel member)Shionogi (Grant/Research Support, Scientific Research Study Investigator, Advisor or Review Panel member)Utility (Advisor or Review Panel member) Vance G. Fowler, Jr., MD, MHS, Achaogen (Consultant)Advanced Liquid Logics (Grant/Research Support)Affinergy (Consultant, Grant/Research Support)Affinium (Consultant)Akagera (Consultant)Allergan (Grant/Research Support)Amphliphi Biosciences (Consultant)Aridis (Consultant)Armata (Consultant)Basilea (Consultant, Grant/Research Support)Bayer (Consultant)C3J (Consultant)Cerexa (Consultant, Other Financial or Material Support, Educational fees)Contrafect (Consultant, Grant/Research Support)Debiopharm (Consultant, Other Financial or Material Support, Educational fees)Destiny (Consultant)Durata (Consultant, Other Financial or Material Support, educational fees)Genentech (Consultant, Grant/Research Support)Green Cross (Other Financial or Material Support, Educational fees)Integrated Biotherapeutics (Consultant)Janssen (Consultant, Grant/Research Support)Karius (Grant/Research Support)Locus (Grant/Research Support)Medical Biosurfaces (Grant/Research Support)Medicines Co. (Consultant)MedImmune (Consultant, Grant/Research Support)Merck (Grant/Research Support)NIH (Grant/Research Support)Novadigm (Consultant)Novartis (Consultant, Grant/Research Support)Pfizer (Grant/Research Support)Regeneron (Consultant, Grant/Research Support)sepsis diagnostics (Other Financial or Material Support, Pending patent for host gene expression signature diagnostic for sepsis.)Tetraphase (Consultant)Theravance (Consultant, Grant/Research Support, Other Financial or Material Support, Educational fees)Trius (Consultant)UpToDate (Other Financial or Material Support, Royalties)Valanbio (Consultant, Other Financial or Material Support, Stock options)xBiotech (Consultant) Daniel D. Rhoads, MD, Becton, Dickinson and Company (Grant/Research Support) Michael Jacobs, MBBS, Venatorx Pharmaceuticals, Inc. (Grant/Research Support) Focco van den Akker, PhD, Venatorx Pharmaceuticals, Inc. (Grant/Research Support) David A. Six, PhD, Venatorx Pharmaceuticals, Inc. (Employee) Greg Moeck, PhD, Venatorx Pharmaceuticals, Inc. (Employee) Krisztina M. Papp-Wallace, Ph.D., Merck & Co., Inc. (Grant/Research Support)Spero Therapeutics, Inc. (Grant/Research Support)Venatorx Pharmaceuticals, Inc. (Grant/Research Support)Wockhardt Ltd. (Other Financial or Material Support, Research Collaborator) Robert A. Bonomo, MD, entasis (Research Grant or Support)Merck (Grant/Research Support)NIH (Grant/Research Support)VA Merit Award (Grant/Research Support)VenatoRx (Grant/Research Support)